Rigel Pharmaceuticals Inc RIGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel Reports Third Quarter 2026 Financial Results
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel to Participate in Upcoming September Investor Conferences
Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market
Trading Information
- Previous Close Price
- $45.69
- Day Range
- $43.84–45.94
- 52-Week Range
- $24.95–52.61
- Bid/Ask
- $37.44 / $46.54
- Shares Outstanding
- 18.83M
- Market Cap
- $837.18M
- Volume/Avg
- 151,588 / 257,635
Key Statistics
- Price/Earnings (Normalized)
- 11.33
- Price/Sales
- 3.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 174
- Website
- https://www.rigel.com
Valuation
Metric | RIGL |
|---|---|
Price/Earnings (Normalized) | 11.33 |
Price/Book Value | 1.88 |
Price/Sales | 3.08 |
Price/Cash Flow | 9.44 |
Price/Earnings
RIGL
Financial Strength
Metric | RIGL |
|---|---|
Quick Ratio | 1.98 |
Current Ratio | 2.39 |
Interest Coverage | 18.17 |
Quick Ratio
RIGL
Profitability
Metric | RIGL |
|---|---|
Return on Assets (Normalized) | 69.51% |
Return on Equity (Normalized) | 90.06% |
Return on Invested Capital (Normalized) | 80.72% |
Return on Assets
RIGL
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%JlKB@@ | LOCK|^^px> | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|XtT$>& | LOCK|SH$? | $99B | |||
| Moderna Inc MRNA | LOCK|jZsfX! | LOCK|<Y | $90B | |||
| argenx SE ADR ARGX | LOCK|VMfQYZ | LOCK|Ks | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|z&$kvq | LOCK|?<w | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|QMp@ZY< | LOCK|RFYT@ | $31B | |||
| Incyte Corp INCY | LOCK|Tz?hWCj | LOCK|Z&G | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|dZjvJ%J | LOCK|mFb% | $22B | |||
| BioNTech SE ADR BNTX | LOCK|Qt$#zm@ | LOCK|t< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|#sq^#L! | LOCK|$$# | $16B |
United States